论文部分内容阅读
[目的]总结cetuximab联合化疗治疗2例NSCLC的经验并同时综述文献,期望了解cetuximab治疗肺癌的现状。[方法]回顾性分析中山大学肿瘤防治中心应用cetuximab联合GP方案化疗治疗的2例NSCLC患者的疗效和毒副反应;再从PubMed数据库中搜集cetuximab联合化疗治疗NSCLC的临床文献进行综述。[结果]①2例NSCLC患者PR(接近CR)和SD各1例,都是3周内出现皮疹,分别为Ⅱ～Ⅲ度和Ⅰ度,化疗相关毒副反应分别是Ⅲ～Ⅳ度骨髓抑制。②共计8篇一线治疗文献和2篇二线治疗文献入选进行了综述。③一线治疗文献中6篇为非对照研究,RR和OS均不比单纯标准化疗方案差;另外2篇随机对照研究显示cetuximab增加疗效。④Cetuximab联合标准化疗方案治疗NSCLC是安全的,ce-tuximab相关的主要副作用是皮疹,发生率高达88.6%。[结论]Cetuximab与NSCLC标准一线化疗方案PC、NP、GP等联合疗效稍微优于单纯标准化疗方案。
[Objective] To summarize the experience of cetuximab combined with chemotherapy for 2 cases of NSCLC and to review the literature at the same time, and to understand the current status of cetuximab in the treatment of lung cancer. [Methods] The curative effect and toxicity of two NSCLC patients treated with cetuximab combined with GP regimen chemotherapy in Cancer Center of Sun Yat-sen University were analyzed retrospectively. The clinical data of cetuximab combined with chemotherapy in NSCLC were collected from PubMed database. [Results] There was a rash in 2 patients with PR (close to CR) and 1 SD each in 2 NSCLC patients. The rashes were grade II-III and degree I, respectively. The chemotherapy-related side effects were grade III-IV myelosuppression. ② A total of 8 first-line treatment literature and two second-line treatment literature were reviewed. ③ The first-line treatment literature 6 non-controlled study, RR and OS are not worse than the standard chemotherapy alone; the other two randomized controlled studies have shown that cetuximab increased efficacy. ④Ceuximab combined with standard chemotherapy regimen for the treatment of NSCLC is safe, the main side effect associated with ce-tuximab is rash, the incidence of up to 88.6%. [Conclusion] The combined effect of Cetuximab and NSCLC standard first-line chemotherapy programs such as PC, NP and GP is slightly better than that of standard chemotherapy alone.